Cell Therapy: The In Vivo Revolution
Six Big Pharma companies have spent $7.5B+ acquiring in vivo cell therapy companies in 18 months. Ex vivo CAR-T economics are broken for chronic disease. The modality is shifting.
1. The Modality Shift: Why Big Pharma Is Abandoning Ex Vivo and Betting $7.5B+ on In Vivo
In the past 12 months, the cell therapy field has undergone a dramatic inflection. Three companies — Takeda, Novo Nordisk, and Galapagos — divested from cell therapy programs entirely. Gilead, the commercial leader in ex vivo CAR-T, reported declining sales for Yescarta and Tecartus. And yet, in the same period, six Big Pharma companies collectively spent over $7.5 billion acquiring in vivo cell therapy companies.
This is not a rejection of cell therapy. It is a rejection of the ex vivo modality’s economics and logistics for chronic disease. The therapeutic principle — targeted depletion of pathogenic cell populations — remains powerful. What’s changing is how that depletion is achieved.
The pattern is unmistakable: AstraZeneca–EsoBiotec ($1B, Jan 2025), AbbVie–Capstan ($2.1B, Jun 2025), Gilead/Kite–Interius ($350M, 2025), BMS–Orbital ($1.5B, Oct 2025), Gilead/Kite–Pregene ($1.6B, Nov 2025), J&J–Kelonia (collaboration, 2025), Novartis–Vyriad (collaboration, 2025), and Eli Lilly–Orna ($2.4B, Feb 2026). Every deal targets the same thesis: in vivo genetic reprogramming of a patient’s own T-cells, bypassing the manufacturing bottleneck that has constrained ex vivo CAR-T since its inception.
Yesterday’s deal (Feb 9, 2026): Eli Lilly announced the acquisition of Orna Therapeutics for up to $2.4 billion. Orna’s platform uses engineered circular RNA (oRNA) delivered via lipid nanoparticles to transiently express CAR constructs on a patient’s T-cells in vivo. Lead asset ORN-252 (CD19) is described as “clinical-trial ready” for B-cell-mediated autoimmune diseases. This is Lilly’s first major move into cell therapy — and part of a $7.5B+ wave of in vivo deals across six Big Pharma companies in 18 months.
2. Ex Vivo CAR-T: Transformative Science, Broken Economics
Approved ex vivo CAR-T products have transformed hematologic oncology. Six FDA-approved products are now on the market, delivering complete response rates of 40–70% in malignancies that previously had no effective options. For patients with relapsed/refractory large B-cell lymphoma or multiple myeloma, CAR-T therapy has been genuinely curative in a meaningful fraction.
But the modality is fundamentally constrained by four interlocking problems:
Manufacturing
Each treatment is a bespoke, patient-specific manufacturing process. Leukapheresis → shipping → viral vector transduction → expansion → quality testing → shipping back → infusion. Vein-to-vein time: 3–6 weeks. Some patients progress and die while waiting for their cells.
Cost
$373K–$475K per treatment for the CAR-T product alone. Add hospitalization, lymphodepleting chemotherapy, CRS/ICANS management, and the total cost often exceeds $500K per patient. Payers are reluctant to expand coverage beyond last-line hematologic malignancies.
Safety
Cytokine release syndrome (CRS) in 60–90% of patients. Immune effector cell-associated neurotoxicity syndrome (ICANS) in 20–60%. Grade 3+ CRS in 5–20%. Requires inpatient monitoring, often ICU-level. In November 2023, FDA added a boxed warning for secondary T-cell malignancies across all approved CAR-T products.
Scalability & Commercial Reality
Manufacturing infrastructure cannot scale to meet demand. Treatment slots are rationed. Total ex vivo CAR-T market is ~$4–5B globally in 2025, well below initial projections. Gilead’s Yescarta/Tecartus are declining ~10–15% YoY. BMS’s Abecma is being cannibalized by J&J’s Carvykti. Carvykti is the only product with strong growth trajectory.
3. The Autoimmune Opportunity Changes Everything
The catalyst for the in vivo revolution came from an unexpected direction: autoimmune disease. In 2022, Mackensen et al. published landmark data in the New England Journal of Medicine showing that CD19 CAR-T therapy achieved complete B-cell depletion and drug-free remission in patients with severe systemic lupus erythematosus. Patients went off all immunosuppressive medication — unprecedented in rheumatology.
Subsequent studies confirmed the same pattern in systemic sclerosis, myasthenia gravis, and inflammatory myopathy. The immunological reset provided by deep B-cell depletion appeared to break the cycle of autoimmunity in ways that chronic immunosuppression never could.
But the risk-benefit calculus is entirely different in autoimmune disease vs. oncology. Cancer patients accept lymphodepleting chemotherapy, weeks of hospitalization, CRS risk, and T-cell malignancy warnings because the alternative is death. Autoimmune patients have chronic, manageable disease. They will not accept $500K, 3–6 weeks inpatient, chemotherapy conditioning, and T-cell malignancy risk for a disease they can manage with existing drugs.
Why In Vivo CAR-T Is Essential for Autoimmune
The autoimmune market is 10–100x larger than hematologic malignancies. Lupus alone: ~200K patients in the US. Rheumatoid arthritis: 1.3M. Multiple sclerosis: 1M. But this market is only addressable with a modality that is: off-the-shelf, outpatient, requires no lymphodepletion or leukapheresis, is redosable, and is affordable. Total addressable autoimmune market for cell therapies: estimated $50–100B+ if the modality works.
4. In Vivo CAR-T: How It Works
Interactive Dashboard: Explore all 38+ in vivo CAR-T programs, delivery platforms, and clinical data in our In Vivo CAR-T Competitive Landscape tracker.
Three main approaches to in vivo cell therapy are being pursued, each with distinct trade-offs:
| Approach | How It Works | Key Companies | Advantages | Risks |
|---|---|---|---|---|
| LNP + mRNA/circRNA | Lipid nanoparticles deliver mRNA or circular RNA encoding CAR construct. Patient’s own T-cells transiently express CAR. | Orna (Lilly), Capstan (AbbVie), Orbital (BMS) | Off-the-shelf, no genomic integration, redosable, transient expression (safety advantage) | Transient = may need redosing. LNP tropism challenges (getting to T-cells, not liver). |
| Lentiviral in vivo | Engineered lentiviral vectors delivered IV that selectively transduce T-cells in vivo, integrating CAR gene permanently. | Umoja Biopharma, EsoBiotec (AZ) | Permanent integration (one-shot potential), proven vector biology | Insertional mutagenesis risk (like ex vivo). Manufacturing complexity of viral vectors. |
| T-cell engagers (alternative) | Bispecific antibodies that redirect T-cells to target (e.g., CD19×CD3) without any genetic modification. | Regeneron, multiple companies | Off-the-shelf, simple IV infusion, no genetic modification, proven modality | Continuous dosing required, no T-cell memory, CRS still occurs, not true cell therapy. |
Circular RNA: Orna’s Key Differentiator
Orna’s platform uses engineered circular RNA (oRNA), which forms a covalently closed loop that is significantly more stable than linear mRNA. Linear mRNA is degraded by exonucleases within hours; circular RNA lacks free 5′ and 3′ ends, making it resistant to this degradation. This means longer protein expression from each dose — potentially bridging the gap between transient mRNA (hours-to-days) and permanent viral integration (forever). For autoimmune disease, where the goal is a transient B-cell depletion that allows immune reconstitution, this “Goldilocks” duration may be ideal.
5. The $7.5B+ In Vivo M&A Wave — Deal Landscape
Full Deal Tracker: See all M&A and collaboration deals with valuation details in our Interactive Dashboard.
| Deal | Buyer | Target | Value | Date | Technology | Lead Program | Target Indication |
|---|---|---|---|---|---|---|---|
| AZ–EsoBiotec | AstraZeneca | EsoBiotec | ~$1B ($425M upfront) | Early 2025 | Lentiviral in vivo | BCMA CAR-T | Autoimmune |
| AbbVie–Capstan | AbbVie | Capstan Therapeutics | $2.1B | Jun 2025 | LNP-delivered in vivo CAR-T | CD19 in vivo CAR-T | Autoimmune |
| Gilead/Kite–Interius | Gilead/Kite | Interius BioTherapeutics | $350M | 2025 | In vivo CAR-T | INT2104 (CD20) | Autoimmune |
| BMS–Orbital | BMS | Orbital Therapeutics | $1.5B | Oct 2025 | Circular RNA platform | Engineered RNA cell therapies | Autoimmune + Oncology |
| Lilly–Orna | Eli Lilly | Orna Therapeutics | Up to $2.4B | Feb 9, 2026 | Circular RNA + LNP | ORN-252 (CD19 in vivo CAR-T) | B-cell autoimmune |
| Gilead/Kite–Pregene | Gilead/Kite | Pregene Biopharma | $1.6B | Nov 2025 | In vivo CAR-T | In vivo CAR-T pipeline | Autoimmune + Oncology |
| J&J–Kelonia | J&J | Kelonia Therapeutics | Collaboration | 2025 | Retroviral in vivo | KLN-1010 (BCMA) | Oncology + autoimmune |
| Novartis–Vyriad | Novartis | Vyriad | Collaboration | 2025 | In vivo CAR-T | In vivo reprogramming | Autoimmune |
Every major pharma is now placing a bet in this space. AstraZeneca, AbbVie, Gilead/Kite (two deals), BMS, Lilly, J&J, and Novartis have collectively deployed $7.5B+ in 18 months on in vivo cell therapy acquisitions and collaborations. Notably, Gilead — the largest ex vivo CAR-T commercial player (Yescarta, Tecartus) — made two in vivo deals, signaling that even the incumbent recognizes the modality shift.
6. Competitive Landscape — Who Has What
Full Pipeline Tracker: Compare all 38+ programs with clinical data, delivery platforms, and catalyst timelines in our Interactive Dashboard.
| Company | Approach | Key Asset | Target | Stage | RNA Type | Delivery | Autoimmune Focus |
|---|---|---|---|---|---|---|---|
| Eli Lilly (Orna) | In vivo CAR-T | ORN-252 | CD19 | Phase 1-ready (IND exp H1 2026) | Circular RNA (oRNA) | Proprietary LNP | Yes — B-cell autoimmune |
| AbbVie (Capstan) | In vivo CAR-T | Undisclosed | CD19 (likely) | Preclinical/IND-enabling | mRNA | LNP | Yes — autoimmune |
| AstraZeneca (EsoBiotec) | In vivo CAR-T | EBO-101 | BCMA | Clinical Data (Lancet 2025) | Lentiviral | Lentiviral vector | Yes — autoimmune |
| BMS (Orbital) | Engineered RNA | Undisclosed | Multiple | Preclinical | Circular RNA | TBD | Yes + Oncology |
| Gilead/Kite (Interius) | In vivo CAR-T | INT2104 | CD20 | Clinical | TBD | TBD | Autoimmune |
| Umoja Biopharma | In vivo CAR-T | UB-VV111 | CD19 | Phase 1 (NCT06260696, Fast Track) | N/A | Lentiviral (VivoVec) | Oncology first, autoimmune planned |
| Sana Biotechnology | In vivo CAR-T | Multiple | CD19 | Preclinical | Fusogen-delivered | Engineered fusogens | Yes — autoimmune |
| Kelonia Therapeutics (J&J) | In vivo CAR-T | KLN-1010 | BCMA | Clinical Data (ASH 2025) | N/A | Retroviral | Oncology + autoimmune |
| Novartis (Vyriad) | In vivo CAR-T | Undisclosed | Undisclosed | Preclinical (collaboration) | TBD | TBD | Autoimmune |
| AbbVie (Capstan) | In vivo CAR-T | CPTX-61 | CD19 | Clinical Data | mRNA | LNP | Yes — autoimmune |
| MagicRNA | In vivo CAR-T | Undisclosed | CD19 | Clinical Data (NEJM 2025) | mRNA | LNP | Autoimmune (lupus) |
| Sail Biomedicines | In vivo CAR-T | Undisclosed | CD19 | Preclinical | mRNA (Endless RNA™) | LNP | Yes — autoimmune |
| Ensoma | In vivo gene therapy | Undisclosed | Multiple | Preclinical | N/A | Engenious™ (viral vector) | Hematology + autoimmune |
The landscape has expanded beyond CD19 to include BCMA and CD20 targets. Six programs now have clinical data (MagicRNA, Capstan/AbbVie, EsoBiotec/AZ, Kelonia/J&J, Umoja, Gilead/Interius), up from zero 12 months ago. Competition increasingly centers on delivery platform differentiation.
7. Ex Vivo CAR-T — Approved Products and Commercial Reality
| Product | Company | Target | Indication | Year Approved | List Price | 2025 Revenue Est |
|---|---|---|---|---|---|---|
| Kymriah | Novartis | CD19 | ALL, DLBCL | 2017 | $475K | ~$500M (declining) |
| Yescarta | Gilead/Kite | CD19 | LBCL, FL | 2017 | $373K | ~$1.2B (declining) |
| Tecartus | Gilead/Kite | CD19 | MCL, ALL | 2020 | $373K | ~$200M (declining) |
| Breyanzi | BMS | CD19 | LBCL | 2021 | $410K | ~$600M |
| Abecma | BMS | BCMA | Multiple myeloma | 2021 | $419K | ~$400M (losing to Carvykti) |
| Carvykti | J&J/Legend | BCMA | Multiple myeloma | 2022 | $465K | ~$1.5B (growing) |
Total ex vivo CAR-T market ~$4–5B globally in 2025. Carvykti is the only product with strong growth trajectory. The others are flat or declining, constrained by manufacturing capacity, high cost, and competition from bispecific T-cell engagers.
8. The Debate: In Vivo CAR-T vs. T-Cell Engagers vs. Ex Vivo CAR-T
Ex vivo CAR-T advocates say:
Proven deep and durable responses in cancer. Permanent genomic integration means true one-shot potential. Growing autoimmune data — Mackensen’s lupus data showed drug-free remission, and Kyverna’s KYV-101 is in clinical trials for myasthenia gravis. Manufacturing will improve over time with automation and allogeneic approaches.
T-cell engager advocates say:
Already commercial — Tecvayli, Elrexfio, and Columvi are approved bispecific T-cell engagers in hematologic malignancies. Off-the-shelf, no genetic modification, simpler manufacturing. Growing autoimmune pipeline (CD19×CD3 bispecifics). But: require continuous dosing, produce no T-cell memory, and CRS still occurs. Not true cell therapy — they redirect existing T-cells rather than reprogram them.
In vivo CAR-T advocates say:
Combines the best of both — the genetic programming of CAR-T with the off-the-shelf convenience of engagers. No leukapheresis, no lymphodepletion, outpatient administration, potentially redosable. Early clinical validation is emerging: MagicRNA published first-in-human data in NEJM (2025) showing transient CAR-T activity in lupus patients, and Capstan/AbbVie reported B-cell depletion with LNP-delivered in vivo CAR-T. The LNP delivery challenge — getting RNA into T-cells rather than liver — remains the key technical hurdle at scale.
The Honest Answer
One size does not fit all. Different indications may require different modalities. Deep B-cell depletion for severe lupus may need permanent ex vivo CAR-T. Mild-to-moderate autoimmune disease may be better served by transient in vivo approaches. Cancer may continue to favor ex vivo for its proven durability. The companies that match the right modality to the right indication will win.
9. Bull/Bear Case for In Vivo CAR-T
Bull Case
- $7.5B+ in Big Pharma M&A validates the thesis — six acquirers in 18 months
- Autoimmune market is 10–100x larger than hematologic oncology (lupus, RA, MS = millions of patients)
- Off-the-shelf + outpatient + redosable = commercially scalable modality
- Circular RNA provides longer expression than mRNA, potentially solving the durability gap
- First-mover advantage: Lilly/Orna’s ORN-252 could be first-in-class in vivo CAR-T in humans
Bear Case
- Early human data (MagicRNA NEJM, Capstan/AbbVie) shows transient CAR-T activity but durability and dose-response remain unproven
- LNP delivery to T-cells (not liver) partially solved in early trials but unproven at scale — efficiency and biodistribution remain key risks
- Transient expression means repeated dosing — cost advantage over ex vivo unclear
- T-cell engagers (bispecifics) may be “good enough” and are years ahead clinically
- Insertional mutagenesis risk for lentiviral approaches (same concern as ex vivo)
- Regulatory path unclear — FDA has no precedent for in vivo genetic modification for autoimmune disease
Upcoming Catalysts
Key Sources
- Mackensen A et al. “Anti-CD19 CAR T cells for refractory systemic lupus erythematosus.” NEJM 2022; 387:2055-2064. PubMed
- Eli Lilly press release. “Lilly to Acquire Orna Therapeutics.” Feb 9, 2026.
- AbbVie press release. “AbbVie to Acquire Capstan Therapeutics.” Jun 2025.
- BMS press release. “BMS to Acquire Orbital Therapeutics.” Oct 2025.
- Gilead Sciences. Q3 2025 Earnings Report — Yescarta and Tecartus sales decline.
- FDA Safety Communication. “Risk of T-cell Malignancy Following BCMA- and CD19-Directed Autologous CAR T-cell Therapies.” Nov 2023.
- MedCity News. “Eli Lilly Expands Its In Vivo Ambitions with Orna Therapeutics Acquisition.” Feb 2026.
- STAT News. “Eli Lilly to buy Orna Therapeutics in $2.4B deal.” Feb 2026.
- MagicRNA et al. “First-in-human in vivo CAR-T via LNP-delivered mRNA in systemic lupus erythematosus.” NEJM 2025.
- EsoBiotec/AstraZeneca. “In vivo lentiviral CAR-T (BCMA) clinical data.” The Lancet 2025.
- Kelonia Therapeutics. “KLN-1010 (BCMA) in vivo retroviral CAR-T data.” ASH 2025.
- Martínez-Banaclocha H et al. “In vivo CAR-T cell therapy: current landscape and future directions.” IJMS 2025.